| Summary: | Part A:
Currently there are about 100 antibody formulations available for the treatment of disease, ranging from migraine prevention, multiple sclerosis and leukaemia. This project will review the development of such formulations and how they relate to antibody subclass structure, stability, storage, prevention of aggregation and administration, costs and safety to patients. The review will include comparative advantages and challenges of intravenous and subcutaneous administration and how challenges of delivery of high concentration formulations (including the viscosity problem) are dealt with. This review will be of great value to the newly reforming NCMH Business Centre based at Sutton Bonington which will act as an advisory and scientific Facility for Biopharma companies such as Astra Zeneca, Arecor, Glaxo Smith Kline, Sanofi and specialising in biopolymer therapeutics and vaccines.
Part B:
The aim of the study was to understand the protein-protein interactions in a non-aqueous
solvents allow higher concentration, focusing on the stability of an antibody fragment, using the ultracentrifuge and dynamic light scattering with software to analyse and understand the protein-protein interactions with Iso-propyl alcohol (IPA) as the solvent. The comparison is done between with buffer and IPA to better understand the characterization. Instabilities and aggregation were also observed for IPA and showed it to be non – suitable for higher concentration formulations of antibodies.
|
|---|